FY2017 Earnings Estimate for Paratek Pharmaceuticals, Inc. (PRTK) Issued By Gabelli
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) – Research analysts at Gabelli raised their FY2017 earnings per share (EPS) estimates for shares of Paratek Pharmaceuticals in a report issued on Thursday. Gabelli analyst K. Kedra now expects that the specialty pharmaceutical company will earn ($3.20) per share for the year, up from their previous forecast of ($3.50). Gabelli also issued estimates for Paratek Pharmaceuticals’ FY2018 earnings at ($2.80) EPS, FY2019 earnings at ($2.75) EPS and FY2020 earnings at ($1.35) EPS.
Other analysts have also recently issued research reports about the stock. BidaskClub cut shares of Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. HC Wainwright upped their price objective on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, July 18th. Cantor Fitzgerald set a $50.00 price objective on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, July 17th. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Thursday, April 20th. Finally, Raymond James Financial, Inc. assumed coverage on shares of Paratek Pharmaceuticals in a research note on Thursday, May 18th. They set a “strong-buy” rating and a $36.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $37.44.
ILLEGAL ACTIVITY WARNING: “FY2017 Earnings Estimate for Paratek Pharmaceuticals, Inc. (PRTK) Issued By Gabelli” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/08/07/fy2017-earnings-estimate-for-paratek-pharmaceuticals-inc-prtk-issued-by-gabelli.html.
Paratek Pharmaceuticals (PRTK) opened at 19.50 on Monday. Paratek Pharmaceuticals has a one year low of $9.80 and a one year high of $26.10. The company has a 50 day moving average of $22.99 and a 200-day moving average of $19.72. The company’s market cap is $538.20 million.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million during the quarter, compared to the consensus estimate of $7.50 million.
A number of hedge funds have recently made changes to their positions in PRTK. Victory Capital Management Inc. acquired a new stake in shares of Paratek Pharmaceuticals during the first quarter valued at about $630,000. Nine Chapters Capital Management LLC purchased a new position in Paratek Pharmaceuticals during the first quarter valued at $258,000. Bank of New York Mellon Corp raised its position in Paratek Pharmaceuticals by 17.5% in the first quarter. Bank of New York Mellon Corp now owns 84,045 shares of the specialty pharmaceutical company’s stock valued at $1,618,000 after buying an additional 12,505 shares during the last quarter. Falcon Point Capital LLC purchased a new position in Paratek Pharmaceuticals during the first quarter valued at $200,000. Finally, C WorldWide Group Holding A S purchased a new position in Paratek Pharmaceuticals during the first quarter valued at $1,540,000. 77.36% of the stock is owned by institutional investors.
In related news, CFO Douglas W. Pagan sold 4,595 shares of the company’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $25.00, for a total transaction of $114,875.00. Following the completion of the sale, the chief financial officer now owns 51,000 shares of the company’s stock, valued at approximately $1,275,000. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Adam Woodrow sold 3,800 shares of the company’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total transaction of $89,604.00. Following the sale, the vice president now directly owns 69,500 shares of the company’s stock, valued at approximately $1,638,810. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,960 shares of company stock valued at $524,342. 4.90% of the stock is owned by corporate insiders.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.